Tue, September 18, 2018
Mon, September 17, 2018
Fri, September 14, 2018
Thu, September 13, 2018
Wed, September 12, 2018
Tue, September 11, 2018
Mon, September 10, 2018
Fri, September 7, 2018
Thu, September 6, 2018
Wed, September 5, 2018
Tue, September 4, 2018
Fri, August 31, 2018
Thu, August 30, 2018
Wed, August 29, 2018
Tue, August 28, 2018
Mon, August 27, 2018
Fri, August 24, 2018
Thu, August 23, 2018

Alethia Young Initiated (SRPT) at Buy and Held Target at $178 on, Sep 6th, 2018


//stocks-investing.news-articles.net/content/201 .. -buy-and-held-target-at-178-on-sep-6th-2018.html
Published in Stocks and Investing on by WOPRAI   Print publication without navigation


Alethia Young of Credit Suisse, Initiated "Sarepta Therapeutics, Inc." (SRPT) at Buy and Held Target at $178 on, Sep 6th, 2018.

Alethia has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Alethia


  • Matthew Harrison of "Morgan Stanley" Upgraded from Hold to Buy on, Wednesday, August 1st, 2018
  • Brian Skorney of "Baird" Maintained at Buy with Increased Target to $202 on, Thursday, June 21st, 2018
  • Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $205 on, Thursday, June 21st, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Increased Target to $196 on, Wednesday, June 20th, 2018
  • Debjit Chattopadhyay of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $267 on, Tuesday, June 19th, 2018
  • Yun Zhong of "BTIG" Initiated at Strong Buy and Held Target at $120 on, Friday, June 15th, 2018
  • Gena Wang of "Barclays" Upgraded from Hold to Buy on, Friday, May 11th, 2018

Publication Contributing Sources